Profile data is unavailable for this security.
About the company
CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD. is a Taiwan-based company principally engaged in the manufacture and distribution of biotechnology products and chemical synthetic products. The Company's biotechnology products include pravastatin, rapamycin, tacrolimus, everolimus, mycophenolate mofetil, mycophenolic acid sodium and others. Its non-biotechnology products include methocarbamol, guaifenesin, trandolapril, fluconazole, olopatadine, dexbromopheniramine maleate and glipizide, among others. Its products are applied in the manufacture of drugs for treatment of cough, diabetes, cardiovascular diseases, high blood pressure and immune system diseases. The Company distributes its products within domestic market and to overseas markets, including the rest of Asia, the Americas and Europe.
- Revenue in TWD (TTM)977.79m
- Net income in TWD-102.95m
- Incorporated1964
- Employees243.00
- LocationChunghwa Chemical Synthesis & Biotech Co LtdNo.1Tung-Hsing Street, Shu-Lin DistrictNEW TAIPEI 238TaiwanTWN
- Phone+886 286843318
- Fax+886 286843202
- Websitehttp://www.ccsb.com.tw
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chunghwa Chemical Synthsis&Biotech CoLtd | 977.79m | -102.95m | 2.07bn | 243.00 | -- | 0.6439 | 23.62 | 2.12 | -1.86 | -1.86 | 17.54 | 41.78 | 0.2102 | 0.9037 | 5.40 | -- | -2.21 | 8.04 | -2.45 | 9.34 | 15.54 | 41.53 | -10.53 | 19.02 | 1.10 | -- | 0.2005 | 23.00 | -35.42 | 3.10 | -79.98 | -14.64 | -1.83 | -24.86 |
| Vetnostrum Animal Health Co Ltd | 1.37bn | 119.57m | 2.63bn | 185.00 | 20.75 | 2.01 | 13.56 | 1.92 | 1.74 | 1.74 | 19.77 | 17.95 | 0.9165 | 2.78 | 6.48 | 7,399,816.00 | 8.00 | 7.64 | 9.81 | 10.10 | 31.85 | 31.00 | 8.73 | 9.19 | 2.18 | 73.65 | 0.0174 | 49.57 | 7.17 | 3.68 | 49.15 | 3.98 | -30.60 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Dimensional Fund Advisors LPas of 08 Jan 2026 | 477.00k | 0.62% |
| American Century Investment Management, Inc.as of 08 Jan 2026 | 113.00k | 0.15% |
| Dimensional Fund Advisors Ltd.as of 30 Nov 2025 | 72.05k | 0.09% |
| DFA Australia Ltd.as of 31 Dec 2025 | 9.66k | 0.01% |
